NCT04423718

Brief Summary

In this study researchers want to learn more about changes in visual acuity (clarity of vision) with a high dose treatment with Aflibercept (Eylea) in patients suffering from neovascular age-related macular degeneration (nAMD). Neovascular AMD is an eye disease that causes blurred vision or a blind spot due to abnormal blood vessels that leak fluid or blood into the light sensitive lining inside the eye (retina). The fluid buildup causes the central part of the retina (macula) responsible for sharp, straight-ahead vision to swell and thicken (edema), which distorts vision.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
1,011

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Aug 2020

Typical duration for phase_3

Geographic Reach
25 countries

228 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 8, 2020

Completed
1 day until next milestone

First Posted

Study publicly available on registry

June 9, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

August 11, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 27, 2022

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

September 6, 2023

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 7, 2024

Completed
Last Updated

August 29, 2025

Status Verified

August 1, 2025

Enrollment Period

2 years

First QC Date

June 8, 2020

Results QC Date

July 9, 2023

Last Update Submit

August 6, 2025

Conditions

Keywords

nAMD

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 48

    Visual function of the study eye was assessed at a distance of 4 meters using the ETDRS BCVA letter score. BCVA scale range is 0 (worst) to 100 (best).

    At baseline and Week 48

Secondary Outcomes (11)

  • Change From Baseline in BCVA Measured by the ETDRS Letter Score at Week 60

    At baseline and Week 60

  • Percentage of Participants With no Intraretinal Fluid (IRF) and no Subretinal Fluid (SRF) in Central Subfield at Week 16

    At Week 16

  • Percentage of Participants Gaining at Least 15 Letters in BCVA From Baseline at Week 48

    At baseline and Week 48

  • Percentage of Participants Achieving an ETDRS Letter Score of at Least 69 (Approximate 20/40 Snellen Equivalent) at Week 48

    At Week 48

  • Change in Choroidal Neovascularization (CNV) Size From Baseline to Week 48

    At baseline and Week 48

  • +6 more secondary outcomes

Study Arms (3)

Aflibercept 2q8

ACTIVE COMPARATOR

In the double-masked study part (Years 1 and 2), Aflibercept 2 mg administered every 8 weeks after a loading phase. (Active Comparator) In Year 3, high dose aflibercept administered according to individual patient response. (Experimental)

Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)Drug: Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)

Aflibercept HDq12

EXPERIMENTAL

Aflibercept high dose (HD) administered every 12 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.

Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Aflibercept HDq16

EXPERIMENTAL

Aflibercept high dose administered every 16 weeks after an initiation phase. Treatment intervals adjusted according to individual patient response.

Drug: Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

Interventions

Solution in Vial, intravitreal (IVT) injection

Aflibercept 2q8Aflibercept HDq12Aflibercept HDq16

Solution in Vial, 2 mg, intravitreal (IVT) injection

Aflibercept 2q8

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Active subfoveal CNV secondary to nAMD, including juxtafoveal lesions that affect the fovea as assessed in the study eye.
  • Total area of CNV (including both classic and occult components) must comprise greater than 50% of the total lesion area in the study eye.
  • BCVA ETDRS letter score of 78 to 24 (corresponding to a Snellen equivalent of approximately 20/32 to 20/320) in the study eye.
  • Decrease in BCVA determined to be primarily the result of nAMD in the study eye.
  • Presence of IRF and/or SRF affecting the central subfield of the study eye on OCT.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of highly effective contraception for those participating in clinical studies.
  • At least one BCVA value and one central subfield retinal thickness (CST) value from measurements at one of the following visits: Visit 24 (Week 84), Visit 25 (Week 88) or Visit 26 (Week 92).
  • Participant is enrolled at a site that participates in the extension period.

You may not qualify if:

  • Causes of CNV other than nAMD in the study eye.
  • Scar, fibrosis, or atrophy involving the central subfield in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the central subfield in the study eye.
  • Uncontrolled glaucoma (defined as IOP \>25 mmHg despite treatment with anti-glaucoma medication) in the study eye.
  • History of idiopathic or autoimmune uveitis in the study eye.
  • Myopia of a spherical equivalent of at least 8 diopters in the study eye prior to any refractive or cataract surgery.
  • History or clinical evidence of diabetic retinopathy, diabetic macular edema, or any retinal vascular disease other than nAMD in either eye.
  • Evidence of extraocular or periocular infection or inflammation (including infectious blepharitis, keratitis, scleritis, or conjunctivitis) in either eye at the time of screening/randomization.
  • Uncontrolled blood pressure (defined as systolic \>160 mmHg or diastolic \>95 mmHg).
  • Any prior or concomitant ocular (in the study eye) or systemic treatment (with an investigational or approved, anti-VEGF or other agent) or surgery for nAMD, except dietary supplements or vitamins.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (235)

Arizona Retina & Vitreous Consultants - Central Phoenix Phoenix

Phoenix, Arizona, 85021-8865, United States

Location

Retina Consultants of Orange County - Fullerton

Fullerton, California, 92835, United States

Location

Northern California Retina Vitreous Associates - Mountain View Office

Mountain View, California, 94040, United States

Location

Azul Vision Pasadena

Pasadena, California, 91107, United States

Location

Retina Consultants San Diego - Poway

Poway, California, 92064, United States

Location

Retina Consultants of Southern California

Redlands, California, 92374, United States

Location

Kaiser Permanente Riverside Medical Center - Cardiology

Riverside, California, 92505, United States

Location

Perlman Medical Offices at UC San Diego Health - Endocrinology

San Diego, California, 92037, United States

Location

Retina Consultants of Southern Colorado, PC

Colorado Springs, Colorado, 80909, United States

Location

New England Retina Associates

New London, Connecticut, 06320, United States

Location

Rand Eye Institute

Deerfield Beach, Florida, 33064, United States

Location

Retina Group of Florida - Fort Lauderdale

Fort Lauderdale, Florida, 33308, United States

Location

Vitreo Retinal Associates PA - The Millennium Center Location

Gainesville, Florida, 32607-2557, United States

Location

Florida Retina Institute- Jacksonville Oak

Jacksonville, Florida, 32204, United States

Location

Florida Eye Associates - Melbourne Main Office

Melbourne, Florida, 32901, United States

Location

Retina Macula Specialists Of Miami - LeJeune Road Office

Miami, Florida, 33126, United States

Location

Florida Retina Institute - Orlando

Orlando, Florida, 32806, United States

Location

Retina Specialty Institute - Pensacola

Pensacola, Florida, 32503, United States

Location

Retina Vitreous Associates of Florida - Saint Petersburg

St. Petersburg, Florida, 33711, United States

Location

Southern Vitreoretinal Associates, P.L. - Tallahassee

Tallahassee, Florida, 32308, United States

Location

Retina Consultants of Hawaii - Pali Momi Medical Center

‘Aiea, Hawaii, 96701, United States

Location

Retina Associates IL

Elmhurst, Illinois, 60126, United States

Location

University Retina and Macula Associates

Oak Forest, Illinois, 60452, United States

Location

Wolfe Eye Clinic - Des Moines

West Des Moines, Iowa, 50266-7705, United States

Location

The Retina Care Center - Baltimore

Baltimore, Maryland, 21209, United States

Location

Ophthalmic Consultants of Boston - Boston

Boston, Massachusetts, 02114, United States

Location

Vitreo Retinal Surgery PA - Edina

Edina, Minnesota, 55435, United States

Location

Retina Consultants of Nevada - Summerlin

Las Vegas, Nevada, 89144, United States

Location

Retina Center of New Jersey

Bloomfield, New Jersey, 07003, United States

Location

NJ Retina - Edison Office

Edison, New Jersey, 08820, United States

Location

Eye Associates of New Mexico - Albuquerque - Retina Center

Albuquerque, New Mexico, 87109, United States

Location

Long Island Vitreoretinal Consultants - Great Neck

Great Neck, New York, 11021, United States

Location

Vitreoretinal Consultants of NY - Hauppauge

Hauppauge, New York, 11788, United States

Location

Ophthalmic Consultants of Long Island

Lynbrook, New York, 11563, United States

Location

Ophthalmic Consultants of the Capital Region - Troy

Troy, New York, 12180, United States

Location

Wake Forest Baptist Health

Winston-Salem, North Carolina, 27157, United States

Location

Midwest Retina - Main Office

Dublin, Ohio, 43016, United States

Location

Retina Northwest - NW Lovejoy

Portland, Oregon, 97210, United States

Location

Retina Consultants, LLC

Salem, Oregon, 97302, United States

Location

Mid Atlantic Retina - Philadelphia / Wills Eye Hospital

Bethlehem, Pennsylvania, 18017, United States

Location

Erie Retinal Research

Erie, Pennsylvania, 16507, United States

Location

Eye Care Specialists - Kingston, PA

Kingston, Pennsylvania, 18704, United States

Location

Charleston Neuroscience Institute - Charleston

Charleston, South Carolina, 29414, United States

Location

Palmetto Retina Center - West Columbia

West Columbia, South Carolina, 29169, United States

Location

Black Hills Regional Eye Institute

Rapid City, South Dakota, 57701, United States

Location

Charles Retina Specialists - Germantown

Memphis, Tennessee, 38119, United States

Location

Vanderbilt University Medical School

Nashville, Tennessee, 37212-1610, United States

Location

Austin Retina Associates - Central

Austin, Texas, 78705, United States

Location

Texas Retina Associates - Fort Worth

Fort Worth, Texas, 76104, United States

Location

Medical Center Ophthalmology Associates - Northwest

San Antonio, Texas, 78240, United States

Location

Retina Consultants of Texas - San Antonio Medical Center

San Antonio, Texas, 78240, United States

Location

Retina Consultants of Texas (Retina Consultants of Houston) - Texas Medical Center

The Woodlands, Texas, 77384, United States

Location

Retina Consultants of Texas - The Woodlands

The Woodlands, Texas, 77384, United States

Location

The University of Vermont Medical Center (Fletcher Allen Health Care) - Main Campus

Burlington, Vermont, 05401-1473, United States

Location

Spokane Eye Clinical Research

Spokane, Washington, 99204, United States

Location

West Virginia University

Morgantown, West Virginia, 26505, United States

Location

University of Wisconsin - Madison

Madison, Wisconsin, 53792, United States

Location

Organizacion Medica de Investigacion (OMI)

Buenos Aires, Ciudad Auton. de Buenos Aires, C1015ABO, Argentina

Location

OFTALMOS, Instituto Oftalmologico de Alta Complejidad

Buenos Aires, Ciudad Auton. de Buenos Aires, C1120AAN, Argentina

Location

Eyeclinic Albury Wodonga

Albury, New South Wales, 2640, Australia

Location

Marsden Eye Surgery Center

Parramatta, New South Wales, 2150, Australia

Location

Sydney Retina Clinic

Sydney, New South Wales, 2000, Australia

Location

Westmead Hospital

Westmead, New South Wales, 2145, Australia

Location

Hobart Eye Surgeons

Hobart, Tasmania, 7000, Australia

Location

Klinikum Klagenfurt am Wörthersee

Klagenfurt, Carinthia, 9020, Austria

Location

Medizinische Universität Graz

Graz, Styria, 8036, Austria

Location

Kepler Universitätsklinikum Campus III

Linz, Upper Austria, 4020, Austria

Location

Konventhospital Barmherzige Brüder Linz

Linz, Upper Austria, 4021, Austria

Location

Hanusch-Krankenhaus Wien

Vienna, 1140, Austria

Location

SEHAT Pentagram

Sofia, 1309, Bulgaria

Location

Spec. Hosp. for Active Treatment for Eye Diseases Zrenie

Sofia, 1408, Bulgaria

Location

University Multiprofile Hospital For Active Treatment 'Alexandrovska' EAD

Sofia, 1431, Bulgaria

Location

Multiprofile Hospital for Active Treatment Sveta Sofia | Internal Diseases Department

Sofia, 1618, Bulgaria

Location

Specialized Hospital For Active Treatment of Eye Diseases Zora

Sofia, 1784, Bulgaria

Location

Sveta Petka Eye Hospital

Varna, 9000, Bulgaria

Location

St.Joseph's Health Care-London

London, Ontario, N6A 4V2, Canada

Location

Toronto Retina Institute

Toronto, Ontario, M3C 0G9, Canada

Location

Institut de l'Oeil des Laurentides

Boisbriand, Quebec, J7H1S6, Canada

Location

The Second Hospital of Anhui medical university

Hefei, Anhui, 230601, China

Location

Beijing Hospital

Beijing, Beijing Municipality, 100730, China

Location

Beijing Tongren Hospital, Capital Medical University (East)

Beijing, Dongcheng District, 100005, China

Location

The 1st Affiliated Hospital Fujian Medical University

Fuzhou, Fujian, TBC, China

Location

Guangzhou Aier Eye Hospital

Guangzhou, Guangdong, 634050, China

Location

Hebei eye hospital

Hebei, Hebei, 050010, China

Location

Shijiazhuang General Hospital

Shijiazhuang, Hebei, 50000, China

Location

Henan Provincial Eye Hospital

Henan, Henan, 450008, China

Location

Tongji Hosp. of Tongji Med Coll, Huazhong Uni of Sci & Tech.

Wuhan, Hubei, 430030, China

Location

Union Hospt Tongji Medical Colleg. Huazhong univ. Scien&Tech

Wuhan, Hubei, 430030, China

Location

The First People's Hospital of Xuzhou

Xuzhou, Jiangsu, 221002, China

Location

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, 330006, China

Location

The First Affiliated Hospital of NanChang University

Nanchang, Jiangxi, 330006, China

Location

Eye Center of the second Bethune Hospital, jinlin University

Changchun, Jilin, 130022, China

Location

Tonghua Central Hospital

Tonghua, Jilin, 134001, China

Location

Shenyang He Eye Specialist Hospital

Shenyang, Liaoning, 110034, China

Location

People's Hospital of Ningxia Hui Autonomous Region - Opthalmology

Ningxia, Ningxia, 750002, China

Location

The First Affiliated Hospital of Xi'an Jiaotong University

Xi’an, Shanxi, 710061, China

Location

Aier Eye Hospital (Chengdu)

Chengdu, Sichuan, China

Location

The First Affiliated Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830011, China

Location

The 1st Affiliated Hospital of Zhejiang University

Hangzhou, Zhejiang, 310000, China

Location

ZheJiang Provincial People's Hospital

Hangzhou, Zhejiang, 310014, China

Location

The Affiliated Eye Hospital of Wenzhou Medical College

Wenzhou, Zhejiang, 0, China

Location

Beijing Aier Intech Eye Hospital

Beijing, 100000, China

Location

Peking University People's Hospital

Beijing, 100032, China

Location

Chongqing Aier Ophthalmology Hospital

Chongqing, 400020, China

Location

Shanghai Tongji Hospital of Tongji University

Shanghai, 200065, China

Location

Shanghai General Hospital

Shanghai, 200080, China

Location

Tianjin Medical University General Hospital

Tianjin, 300052, China

Location

Tianjin Eye Hospital

Tianjin, 300384, China

Location

Tianjin Medical University Eye Hospital

Tianjin, 300384, China

Location

Fakultní Nemocnice Hradec Kralové

Hradec Králové, 500 05, Czechia

Location

Fakultní nemocnice Ostrava

Ostrava, 708 52, Czechia

Location

Fakultni nemocnice Plzen - Lochotin

Plzen-Lochotin, 323 00, Czechia

Location

Fakultni nemocnice Kralovske Vinohrady

Prague, 10034, Czechia

Location

Charles University in Prague

Prague, 110 00, Czechia

Location

Lexum a.s., Evropska ocni klinika

Prague, 140 00, Czechia

Location

Axon Clinical, s.r.o.

Prague, 150 00, Czechia

Location

AS Ida-Tallinna Keskhaigla - Oftalmoloogiakeskus

Tallinn, 10138, Estonia

Location

Sihtasutus Tartu Ülikooli Kliinikum - Silmakliinik

Tartu, 50406, Estonia

Location

Centre d'Ophtalmologie - Paradis-Monticelli

Marseille, 13008, France

Location

AP-HP - Hopital Lariboisiere

Paris, 75475, France

Location

Centre ophtalmologique Saint-Exupéry

Saint-Cyr-sur-Loire, 37540, France

Location

LTD "Clinic LJ" - Opthalmology

Kutaisi, 4600, Georgia

Location

JSC "Evex Hospitals'

Tbilisi, 0186, Georgia

Location

LTD "Innova"

Tbilisi, 105, Georgia

Location

LTD "Chichua Medical Center MZERA"

Tbilisi, 114, Georgia

Location

Budapest Retina Associates

Budapest, 1133, Hungary

Location

Szent-Gyorgyi Albert Orvostudomanyi Egyetem

Szeged, 6720, Hungary

Location

Rambam Health Corporation

Haifa, 3109601, Israel

Location

Lady Davis Carmel Medical Center

Haifa, 3436212, Israel

Location

Hadassah Hebrew University Hospital Ein Kerem

Jerusalem, 9112001, Israel

Location

Meir Medical Center

Kfar Saba, 4428164, Israel

Location

Chaim Sheba Medical Center

Ramat Gan, 5262000, Israel

Location

Kaplan Medical Center

Rehovot, 7610001, Israel

Location

Assuta Medical Centers - HaShalom

Tel Aviv, 6789140, Israel

Location

Azienda Ospedaliera Policlinico Universitario Tor Vergata

Rome, Lazio, 00133, Italy

Location

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Lazio, 00168, Italy

Location

Fondazione G.B.Bietti Per Lo Studio E La Ricerca In Oftalmologia

Rome, Lazio, 198, Italy

Location

ASST Fatebenefratelli Sacco

Milan, Lombardy, 20122, Italy

Location

Ospedale San Raffaele s.r.l. - Oculistica

Milan, Lombardy, 20132, Italy

Location

Azienda Ospedaliero-Universitaria Di Cagliari

Cagliari, Sardinia, 9042, Italy

Location

A.O. di Perugia

Perugia, Umbria, 6129, Italy

Location

Daiyukai Daiichi Hospital

Ichinomiya, Aichi-ken, 491-8551, Japan

Location

Aichi Medical University Hospital

Nagakute, Aichi-ken, 480-1195, Japan

Location

Nagoya University Hospital

Nagoya, Aichi-ken, 466-8560, Japan

Location

Nagoya City University Hospital

Nagoya, Aichi-ken, 467-8602, Japan

Location

Kokura Memorial Hospital

Kitakyushu, Fukuoka, 802-8555, Japan

Location

Kurume University Hospital

Kurume, Fukuoka, 830-0011, Japan

Location

Southern Tohoku Eye Clinic

Kōriyama, Fukushima, 963-8052, Japan

Location

Gunma University Hospital

Maebashi, Gunma, 371-8511, Japan

Location

Sapporo City General Hospital

Sapporo, Hokkaido, 060-8604, Japan

Location

KKR Sapporo Medical Center

Sapporo, Hokkaido, 062-0931, Japan

Location

Hyogo Prefectural Amagasaki General Medical Center

Amagasaki, Hyōgo, 660-8550, Japan

Location

Kobe University Hospital

Kobe, Hyōgo, 650-0017, Japan

Location

Kozawa Eye Hospital and Diabetes Center

Mito, Ibaraki, 310-0845, Japan

Location

Kanazawa Medical University Hospital

Kahoku-gun, Ishikawa-ken, 920-0293, Japan

Location

Kanazawa University Hospital

Kanazawa, Ishikawa-ken, 920-8641, Japan

Location

Kagawa University Hospital

Kita-gun, Kagawa-ken, 761-0793, Japan

Location

Medical corporation Eiwakai Dannoue Ophthalmology clinic

Kawasaki, Kanagawa, 211-0053, Japan

Location

St. Marianna University Hospital

Kawasaki, Kanagawa, 216-8511, Japan

Location

Otakeganka Tsukimino Clinic

Yamato, Kanagawa, 242-0001, Japan

Location

Mie University Hospital

Tsu, Mie-ken, 514-8507, Japan

Location

Shinshu University Hospital

Matsumoto, Nagano, 390-8621, Japan

Location

Nara Medical University Hospital

Kashihara, Nara, 634-8522, Japan

Location

Oita University Hospital

Yufu, Oita Prefecture, 879-5593, Japan

Location

Kurashiki Medical Center

Kurashiki, Okayama-ken, 710-8522, Japan

Location

Okayama University Hospital

Okayama, Okayama-ken, 700-8558, Japan

Location

University of the Ryukyus Hospital

Nakagami, Okinawa, 903-0215, Japan

Location

Kansai Medical University Hospital

Hirakata, Osaka, 573-1191, Japan

Location

Kansai Medical University Medical Center

Moriguchi, Osaka, 570-8507, Japan

Location

Kindai University Hospital

Osakasayama-shi, Osaka, 589-8511, Japan

Location

The University of Tokyo Hospital

Bunkyo-ku, Tokyo, 113-8655, Japan

Location

St.Luke's International Hospital

Chuoku, Tokyo, 104-8560, Japan

Location

Nishikasai Inouye Eye Hospital

Edogawa-ku, Tokyo, 134-0088, Japan

Location

Tokyo Medical University Hachioji Medical Center

Hachiōji, Tokyo, 193-0998, Japan

Location

Tokiwadai Muranaka Eye Clinic

Itabashi-ku, Tokyo, 174-0071, Japan

Location

National Hospital Organization Tokyo Medical Center

Meguro-ku, Tokyo, 152-8902, Japan

Location

Keio University Hospital

Shinjuku-ku, Tokyo, 160-8582, Japan

Location

Tokyo Women's Medical University Hospital

Shinjuku-ku, Tokyo, 162-8666, Japan

Location

Yamaguchi University Hospital

Ube, Yamaguchi, 755-8505, Japan

Location

University of Yamanashi Hospital

Chūō, Yamanashi, 409-3898, Japan

Location

Akita University Hospital

Akita, 010-8543, Japan

Location

Hayashi Eye Hospital

Fukuoka, 812-0011, Japan

Location

Fukushima Medical University Hospital

Fukushima, 960-1295, Japan

Location

Hiroshima University Hospital

Hiroshima, 734-8551, Japan

Location

University of Miyazaki Hospital

Miyazaki, 889-1692, Japan

Location

Japanese Red Cross Nagasaki Genbaku Hospital

Nagasaki, 852-8511, Japan

Location

Japanese Red Cross Saitama Hospital

Saitama, 330-8553, Japan

Location

Tokushima University Hospital

Tokushima, 770-8503, Japan

Location

Japanese Red Cross Wakayama Medical center

Wakayama, 640-9558, Japan

Location

Yamagata University Hospital

Yamagata, 990-9585, Japan

Location

Department of Ophthalmology

Riga, 1002, Latvia

Location

Latvian American Eye Center

Riga, LV-1009, Latvia

Location

Riga East Clinical University Hospital "Gailezers"

Riga, LV-1038, Latvia

Location

Hospital of LT University of Health Sciences Kaunas Clinics

Kaunas, LT-50161, Lithuania

Location

PI Klaipedos University Hospital

Klaipėda, LT-92288, Lithuania

Location

Vilnius University Hospital Santaros Klinikos

Vilnius, LT-08661, Lithuania

Location

ALM Oftalmolaser - Oftalmologia Medica e Cirurgica

Lisbon, Lisbon District, 1050-078, Portugal

Location

AIBILI

Coimbra, 3000-548, Portugal

Location

Espaco Medico de Coimbra

Coimbra, 3000-548, Portugal

Location

Centro Hospitalar Universitario do Porto

Porto, 4099-001, Portugal

Location

Centro Hospitalar Vila Nova de Gaia e Espinho | Unit 1 - Clinical Research Center

Porto, 4434-502, Portugal

Location

Scientific Research Institution of Ophthalmic Diseases

Moscow, 119021, Russia

Location

FBSI IRTC Eye Microsurgery n.a. acad. S.N. Fyodorov

Moscow, 127486, Russia

Location

Clinical Center of Serbia

Belgrade, 11000, Serbia

Location

Clinical hospital center Zvezdara

Belgrade, 11000, Serbia

Location

Klinicki centar Vojvodine

Novi Sad, 21000, Serbia

Location

National University Hospital Medical Centre

Singapore, 119074, Singapore

Location

Singapore National Eye Centre

Singapore, 168751, Singapore

Location

Fakultna nemocnica Nitra

Nitra, 950 01, Slovakia

Location

Nemocnica s Poliklinikou Trebisov, Svet zdravia a.s.

Trebišov, 075 01, Slovakia

Location

Fakultna nemocnica Trencin

Trenčín, 911 71, Slovakia

Location

Fakultna nemocnica s poliklinikou Zilina

Žilina, 012 07, Slovakia

Location

Nune Eye Hospital - Retina Center Ophthalmology

Seoul, Gangnam-gu, 135-280, South Korea

Location

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggido, 13620, South Korea

Location

Asan Medical Center - Oncology Department

Seoul, Seoul Teugbyeolsi, 05505, South Korea

Location

Pusan National University Hospital

Busan, 49241, South Korea

Location

Inje University Haeundae Paik Hospital

Busan, 612-862, South Korea

Location

Seoul National University Hospital (b)

Seoul, 03080, South Korea

Location

Samsung Medical Center - Oncology Department

Seoul, 06351, South Korea

Location

Instituto Oftalmologico Gomez-Ulla S.L. - Oftalmologia

Santiago de Compostela, A Coruña, 15706, Spain

Location

Hospital Clínic i Provincial de Barcelona

Barcelona, 8036, Spain

Location

Hospital de la Santa Creu i Sant Pau | Gynecology Department

Barcelona, 8041, Spain

Location

Hospital Universitario Reina Sofia - Oftalmologia

Córdoba, 14004, Spain

Location

Hospital General Universitario de Valencia

Valencia, 46014, Spain

Location

Hospital Universitario Y Politecnico La Fe - Oftalmologia

Valencia, 46026, Spain

Location

Hospital Universitario Miguel Servet - Oftalmologia

Zaragoza, 50009, Spain

Location

RétinElysée

Lausanne, Canton of Vaud, 1006, Switzerland

Location

Berner Augenklinik am Lindenhofspital

Bern, TBC, Switzerland

Location

Stadtspital Triemli

Zurich, 8063, Switzerland

Location

Shin Kong Wu Ho-Su Memorial Hospital

Taipei, 111, Taiwan

Location

Taipei Veterans General Hospital

Taipei, 11217, Taiwan

Location

Chang Gung Memorial Hospital at Linkou

Taoyuan District, 33305, Taiwan

Location

Private Enterprise Private Production Company "Acinus", Treatment and Diagnostic Center

Kropyvnytskyi, 25006, Ukraine

Location

Centralna Polyclinica MVS Ukraiiny

Kyiv, 1024, Ukraine

Location

Poltava Regional Clinical Hospital n.a. M.V. Skliphosovskyi

Poltava, 36011, Ukraine

Location

Related Publications (4)

  • Chang A, Sun X, Iida T, Lai TYY, Wong TY, Cheung CMG, Lee WK, Zhang X, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Chen SJ; PULSAR study investigators. Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial. Asia Pac J Ophthalmol (Phila). 2026 Jan 8:100278. doi: 10.1016/j.apjo.2026.100278. Online ahead of print.

  • Lee WK, Wong TY, Chen SJ, Sun X, Cheung CMG, Silva R, Ricci F, Zhang X, Machewitz T, Schulze A, Schmidt-Ott UM, Zhao M, Hasanbasic Z, Leal S, Iida T; PULSAR Study Investigators. Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: Post Hoc Analysis of the PULSAR Randomized Clinical Trial. JAMA Ophthalmol. 2025 Dec 18. doi: 10.1001/jamaophthalmol.2025.5098. Online ahead of print.

  • Korobelnik JF, Lanzetta P, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Sun X, Berliner AJ, Schulze A, Zhao M, Schmelter T, Schmidt-Ott U, Zhang X, Morgan-Warren P, Hasanbasic Z, Vitti R, Chu KW, Reed K, Bhore R, Cheng Y, Bai Z, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology. 2026 Jan;133(1):39-50. doi: 10.1016/j.ophtha.2025.08.022. Epub 2025 Aug 26.

  • Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, Eichenbaum D, Iida T, Xiaodong S, Berliner AJ, Schulze A, Schmelter T, Schmidt-Ott U, Zhang X, Vitti R, Chu KW, Reed K, Rao R, Bhore R, Cheng Y, Sun W, Hirshberg B, Yancopoulos GD, Wong TY; PULSAR Investigators. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024 Mar 23;403(10432):1141-1152. doi: 10.1016/S0140-6736(24)00063-1. Epub 2024 Mar 7.

Related Links

MeSH Terms

Interventions

aflibercept

Results Point of Contact

Title
Therapeutic Area Head
Organization
Bayer

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
LTE60
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Up to Week 108: Participant and Investigator masked. Week 108 to Week 156: Participant and Investigator unmasked to treatment intervals.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 8, 2020

First Posted

June 9, 2020

Study Start

August 11, 2020

Primary Completion

July 27, 2022

Study Completion

August 7, 2024

Last Updated

August 29, 2025

Results First Posted

September 6, 2023

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Locations